sartorius annual report 2019

 

Our technically qualified sales staff sells around 45,000 articles from the field of tools. At year-end 2019, the Group employed 9,016 staff members. In line with its strong growth, Sartorius further increased its number of employees. 21-Oct-2020 . Q4 2020 Sartorius AG Annual Report. The division's respective margin rose due to economies of scale and as a consequence of the change in IFRS 162), from 28.6% to 29.6%. Sartorius shall not assume any liability for the correctness of this translation. Sartorius confirmed its preliminary figures upon publication of its 2019 Annual Report. Sartorius Group 2019 Annual Report 9 love.de.fca-comission.site. elt sich . The Lab Products & Services Division specializes in technologies and products for laboratories in the pharma sector and in life science research as well as in a few additional segments. GÖTTINGEN, Germany, Feb. 18, 2020 /PRNewswire/ -- Sartorius, a leading international partner of life science research and the biopharmaceutical industry, confirmed its preliminary figures upon publication of its 2019 Annual Report today. With respect to the division's underlying EBITDA margin1), management assumes that it will increase to around 30.0% (2018: 29.6%). 2) IFRS 16 required to be applied as of 2019 regulates accounting of lease contracts. 1) Sartorius publishes alternative performance measures that are not defined by international accounting standards. It is classified as operating in the Personal & Laundry Services industry. At year-end 2019, the Group employed 9,016 staff members. Group sales revenue rose in constant currencies by 14.8% (reported: +16.7%) to 1,827.0 million euros. The planned acquisition of parts of Danaher's life science portfolio announced in October 2019 covers, among others, the FortéBio business for label-free biomolecular characterization, as well as chromatography hardware and resins, with which Sartorius would extend its portfolio in the downstream area. The Americas region achieved a 17.4% increase in sales to 629.9 million euros, contributing around 35% to Group revenue. Sartorius projects that it will increase Group sales in fiscal 2020 by 10% to 13%, with the acquisition of Biological Industries, completed at the end of 2019, expected to contribute approx. The positive business performance of our Group resulted in a further rise in the valuation of Sartorius shares. Registration on or use of this site constitutes acceptance of our Terms of Service and Privacy Policy. ), Bioprocess Solutions strong; Lab Products & Services robust. ... 2019. ), Bioprocess Solutions strong; Lab Products & Services robust. Sartorius projects that it will increase Group sales in fiscal 2020 by 10% to 13%, with the acquisition of Biological Industries, completed at the end of 2019, expected to contribute approx. It is classified as operating in the Personal & Laundry Services industry. Sartorius, a leading international partner of life science research and the biopharmaceutical industry, confirmed its preliminary figures upon publication of its 2019 Annual Report today. In Asia | Pacific, Sartorius earned sales of 463.7 million euros (+17.4%), which equates to a share of around 25% of Group revenue. With sales revenue surging 14.8% to just over €1.8 billion and the EBITDA margin up 1.2 percentage points at … nnal Report 2019 The Afnic General Assembly and annual dinner were the occasion for its members and teams to thank Emmanuel Sartorius for his efforts at the head of our association these past six years and to welcome Godefroy Beauvallet, our new Chair. For this reason, please refer to a detailed description of the opportunities and risks as well as the risk management system for the Sartorius Group on pages 57 et seq. Report of the Executive Board; Executive Board; Report of the Supervisory Board; Sartorius Shares; Combined Group Management Report; Consolidated Financial Statements and Notes; Supplementary Information; Annual report 2019. Ordinary shares ended the trading year at around 97% higher, at €345.00. You can access PDF versions of the SAP Integrated Report 2019 and the SAP Annual Report 2019 on Form 20-F at our Investor Relations website www.sap.com/investor. SARTORIUS Werkzeuge GmbH & Co. KG. Annual … All forecasts are based on constant currencies, as in the past years. For the full year of 2019, Sartorius expects to continue to grow profitably. "Over the past years, we have evolved from a product supplier for various sectors into an application-oriented solutions provider for life science research and the biopharmaceutical industry. and 65 et seq. This press release contains forward-looking statements about the future development of the Sartorius Group. Beyond operating business development and the integration of acquisitions, additional topics are on the 2020 agenda at Sartorius. Further, this has resulted in reporting longer-term lease payments as depreciation and, accordingly, in a somewhat higher EBITDA, but does not entail any material changes concerning the Group's relevant net profit or earnings per share. Read or download all reports of the Salzgitter Group. Download 2792 Kb. GÖTTINGEN, Germany, Feb. 18, 2020 /PRNewswire/ -- Sartorius, a leading international partner of life science research and the biopharmaceutical industry, confirmed its preliminary figures upon publication of its 2019 Annual Report today. Made In NYC | The Americas region achieved a 17.4% increase in sales to 629.9 million euros, contributing around 35% to Group revenue. Disclaimer | Based on the company's positive business performance, the Executive Board and the Supervisory Board will submit a proposal to the Annual General Shareholders' Meeting on March 26, 2020, to pay dividends of 0.71 euros per preference share and 0.70 euros per ordinary share. Compared to headcount as of December 31, 2019, this number rose by 756. 3-Month Report 2020 PDF . Stock quotes by finanzen.net. Key performance indicators for fiscal 2019, In millions of €, unless otherwise specified, 1) In constant currencies, abbreviated as "cc" 2) Acc. Annual Report 2018 –2019 n e w y o R k 2 0 1 9. This equates to an 11% increase or around 900 people more than a year ago. Resolutions of the Annual Shareholders' Meeting of Sartorius AG... Sartorius is a corporate partner of the Healthcare... Order intake: all customer orders contractually concluded during the respective reporting period, Underlying EBITDA: earnings before interest, taxes, depreciation and amortization and adjusted for extraordinary items, Relevant net profit: profit for the period after non-controlling interest, adjusted for extraordinary items and non-cash amortization, as well as based on the normalized financial result and corresponding tax effects, CAPEX ratio: investment payments in relation to sales revenue for the same period. Find detailed stats on Sartorius revenue on Craft. Hauptversammlung am 28. Underlying EBITDA1) rose overproportionately again relative to sales, as in the prior year, by 22.4% to 495.8 million euros in 2019; the respective margin was 27.1% (previous year: 25.9%) in line with our guidance. "We will extend our already good position by focusing on fields of the future, such as biosimilars as well as advanced therapies. "The once again very positive development of the Group shows that we have laid a strong foundation for sustained profitable growth by concentrating in both divisions on the dynamic biopharma sector," commented CEO Dr. Joachim Kreuzburg on the past fiscal year. 2018. In particular, the company's customer-facing units, research and development, and production reported staff gains. We are providing you with comprehensive information on MTU Aero Engines by publishing our financial reports and IR presentations for capital-market stakeholders. The Sartorius group is an international pharmaceutical and laboratory equipment supplier, covering the segments of Bioprocess Solutions and Lab Products & Services.. The Bioprocess Solutions Division that offers a wide array of innovative technologies for the manufacture of biopharmaceuticals exceeded its already strong prior-year performance, increasing its sales revenue in constant currencies by 18.1% (reported: +20.0%) to 1,372.1 million euros. Rapport semestriel. As a result, the Group now owns production facilities for cell culture media. The division's respective margin rose due to economies of scale and as a consequence of the change in IFRS 162), from 28.6% to 29.6%. Relevant net profit1) rose by 19.2% from 175.6 million euros a year ago to 209.3 million euros, yielding earnings per ordinary share of 3.06 euros (2018: 2.56 euros) and earnings per preference share of 3.07 euros (2018: 2.57 euros). € 1,827.0m. The division's order intake1) increased by 5.7% (reported: +7.3%) to 460.3 million euros. Group sales revenue rose in constant currencies by 14.8% (reported: +16.7%) to 1,827.0 million euros. All rights reserved. 2019Annual Report 1|ABSTRACT In this annual report, we have summarized the most important research activities of the High Pressure High Tempe-rature Laboratory of Experimental Volcanology and Geophysics and of the Laboratory of New Technologies that were conducted in 2019. This equates to an 11% increase or around 900 people more than a year ago. Contact: Petra Kirchhoff Head of Corporate Communications and Investor Relations +49-(0)551-308-1686[email protected], Cision Distribution 888-776-0942 0,61 Euro je Stammaktie auszuschütten. At the end of 2019, more than 9,000 people were employed at the Group's approximately 60 manufacturing and sales sites, serving customers around the globe. Positive development of the Lab Products & Services Division. As expected, slightly less than one percentage point of this increase was attributable to the IFRS 162) Standard required to be applied for the first time in 2019. A hard copy of the audited consolidated financial statements can also be requested free of charge by sending an email to investor@sap.com or via phone +49 6227 7-67336. The opportunities and risk situation of the Sartorius Group has not materially changed since the publication of its 2019 Annual Report. 2019: SARTORIUS STEDIM BIOTECH SA: HALF-YEAR report of the liquidity contract with th.. EQ. The Sartorius Group continued to make substantial investments in expanding its global capacity, even though, as expected, its CAPEX ratio1) decreased upon the completion of several large projects to 12.3% (2018: 15.2%). Half-year report at 30 June 2018 Aug 2, 2018. This is a translation of the original German-language press release. Wie Sie ukrainische Single Frauen kennenlernen, die Kinder haben. The Bioprocess Solutions Division with its broad product portfolio focusing on single-use solutions helps customers to manufacture biotech medications and vaccines safely and efficiently. Regarding profitability, Sartorius forecasts that its underlying EBITDA margin1) will increase year over year from 27.1% to about 27.5%. 2021-02-21 23:50. (All growth rates for sales revenue and order intake are given in constant currencies.). 40880 Ratingen. Mit einem Umsatzplus von 14,8 % auf etwas mehr als 1,8 Milliarden Euro bei einer um 1,2 Prozentpunkte auf 27,1 % … Sartorius dynamically increased its sales in all regions compared with the previous year. For the Bioprocess Solutions Division, the Executive Board projects sales growth of 11% to 14%, with consolidation of Biological Industries expected to contribute about one percentage point to this gain. Sartorius hat seine sehr dynamische Entwicklung auch 2019 fortgesetzt und das Jahr mit zweistelligen Wachstumsraten bei Umsatz und Ertrag abgeschlossen. 2021-02-21 23:50. 14:20. Global Cell Culture Market Report 2020-2030 Featuring Thermo Fisher Scientific, Corning, Becton, Dickinson and Co, Eppendorf, Merck KGAA, Lonza, Sartorius, Promocell, Danaher and Sartorius 3 Further information is provided on page 28 of the Sartorius 2019 Annual Report This press release contains forward-looking statements about the future development of the Sartorius Group. Group sales revenue rose in constant currencies by 14.8% (reported: +16.7%) to 1,827.0 million euros. Under this proposal, the total amount disbursed would increase by 14.6% to 48.2 million euros from 42.1 million euros a year earlier. The Bioprocess Solutions Division that offers a wide array of innovative technologies for the manufacture of biopharmaceuticals exceeded its already strong prior-year performance, increasing its sales revenue in constant currencies by 18.1% (reported: +20.0%) to 1,372.1 million euros. The division's order intake1) rose significantly as well by 18.0% (reported: +19.9%) to 1,479.3 million euros. Since 2019 and as a result of the change in IFRS 16 accounting principles, CAPEX has been based on cash flow instead of balance sheet computation; CAPEX ratio restated for 2018: 14.9%, Ratio of net debt to underlying EBITDA: quotient of net debt and underlying EBITDA. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such statements. Ultimately, this has led to a somewhat extended balance sheet and thus to a slightly lower equity ratio. Following the closing of this transaction, presently expected around the end of the first quarter of 2020, management will update its full-year guidance accordingly. Relevant net profit1) rose by 19.2% from 175.6 million euros a year ago to 209.3 million euros, yielding earnings per ordinary share of 3.06 euros (2018: 2.56 euros) and earnings per preference share of 3.07 euros (2018: 2.57 euros). Annual Report 2019 PDF; Audio replay of the analyst conference call on April 29, 2020 Audio replay (PIN 868607) Financial Statements 2019 of Epigenomics AG (German–HGB) PDF; 9-Month Report 2019 PDF; 6-Month Report 2019 PDF; 3-Month Report 2019 PDF . At year-end 2019, the Group employed 9,016 staff members. All forecasts are based on constant currencies, as in the past years. In addition, we assume overall stable conditions regarding the global economy and supply chains. These are determined with the aim of improving the comparability of business performance over time and within the industry. These are determined with the aim of improving the comparability of business performance over time and within the industry. Annual Report 2018 PDF; Financial Statements 2018 of Epigenomics AG (German–HGB) PDF For this division, the underlying EBITDA margin1) is forecasted at around 20.0% (2018: 19.6%). : 1 Founded in 1870, the Göttingen-based company currently employs over 9,000 persons. It showed robust performance in a partly challenging economic environment, achieving sales growth of 5.9% (reported: +7.5%) to 454.9 million euros. Equity rose from 973.4 million euros to 1,081.2 million euros at year-end. Preference shares closed the year 2020 at, €343.60 up around 80% from year-end 2019. This gain was fueled by ongoing strong demand across all product categories, particularly in project business in Asia. In line with its strong growth, Sartorius further increased its number of employees. The division's order intake1) increased by 5.7% (reported: +7.3%) to 460.3 million euros. The ratio of capital expenditures (CAPEX) to sales revenue1) is expected to be around 10% (2018: 12.3%). The transaction is presently expected to close around the end of the first quarter of 2020. The above forecast does not consider the acquisition of parts of Danaher's life science portfolio, which was announced on October 21, 2019, and is currently undergoing antitrust clearance. Annual Report 2019/20 Download – PDF 9 MB . First Half Fiscal 2018 Results. The Sartorius Group is a leading international partner of life science research and the biopharmaceutical industry, listed on the German MDAX and TecDAX stock markets. (All growth rates for the regions are in constant currencies.